Zacks Research Analysts Increase Earnings Estimates for AGIO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at Zacks Research lifted their Q3 2026 earnings per share estimates for shares of Agios Pharmaceuticals in a research note issued on Thursday, August 20th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of ($1.79) per share for the quarter, up from their previous estimate of ($1.85). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.80) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.77) EPS, FY2026 earnings at ($6.94) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.44) EPS, Q1 2028 earnings at ($1.23) EPS, Q2 2028 earnings at ($1.05) EPS and FY2028 earnings at ($3.88) EPS.

AGIO has been the topic of a number of other research reports. Bank of America raised their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. HC Wainwright upped their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Citigroup lifted their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Truist Financial decreased their price target on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average target price of $41.25.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $32.64 on Monday. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The stock’s 50 day simple moving average is $35.85 and its 200 day simple moving average is $31.47. The company has a market cap of $1.95 billion, a P/E ratio of -4.66 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $239,582,000. Bellevue Group AG grew its stake in shares of Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after purchasing an additional 124,586 shares during the period. State Street Corp grew its position in shares of Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after acquiring an additional 845,433 shares during the period. Erste Asset Management GmbH increased its holdings in Agios Pharmaceuticals by 1.4% in the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after acquiring an additional 40,000 shares in the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Agios Pharmaceuticals by 3,515.3% in the second quarter. California State Teachers Retirement System now owns 2,478,800 shares of the biopharmaceutical company’s stock valued at $91,988,000 after acquiring an additional 2,410,236 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.